They were ARID1A (tazemetostat, PLX2853), NF1 (trametinib, cobimetinib) and PTEN (GSK2636771, AZD8186) in three IMT patients, and KRAS (trametinib, cobimetinib, binimetinib) in one MT patient (Table S9). This evidence concerns the gene KRAS and inflammatory myofibroblastic tumor.